Salidroside Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via AMPK-Dependent TXNIP/NLRP3 Pathway

Figure 2

Salidroside (SAL) improves serum lipid profiles and alleviates hepatic steatosis in HFD mice. After treatment with SAL (100 mg·kg⁻¹·d⁻¹) for 8 weeks, serum samples and liver tissues were obtained from RD and HFD mice. The levels of serum TC, TG, HDL-C, LDL-C, and NEFA (a) and the levels of AST and ALT (b) were measured, and the liver weight (c) and hepatic lipid content (e) were detected. Liver sections were prepared, hematoxylin-eosin (H & E) staining and Oil Red O staining (d) were carried out, and steatosis, inflammation, ballooning, and NAFLD activity (f) were scored. Scale bar = 200 μm. versus RD mice treated with vehicle; , versus HFD mice treated with vehicle. Values are means ± s.e.m. ((a)–(c) and (f): ; (d) and (e): ).

(a)

(b)

(c)

(d)

(e)

(f)